Spruce Biosciences AI Stock Analysis
Want to see SPRB full AI Analyst Report?
Spruce Biosciences (SPRB) AI Stock Analysis
Spruce Biosciences
(NASDAQ:SPRB)
The score is primarily held back by weak financial performance—persistent losses and significant ongoing cash burn that imply continued reliance on external funding. Technicals are mixed (neutral momentum but still below key longer-term averages), and valuation provides limited support due to negative earnings and no dividend yield data.
Spruce Biosciences (SPRB) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $124.47M
- Dividend Yield
- ―
- Average Volume (3M)
- 86.59K
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- -10.88
- Revenue Growth
- -100.00%
- EPS Growth
- 58.95%
- Country
- US
- Employees
- 22
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Spruce Biosciences Business Overview & Revenue Model
Company Description
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions...
How the Company Makes Money
As a clinical-stage biotech, Spruce Biosciences’ ability to generate revenue is typically driven by external financing and, where applicable, collaboration-related payments rather than recurring product sales. Product revenue from commercialized drug...
Spruce Biosciences Financial Statement Overview
Summary
Overall financial quality is weak: revenue is inconsistent and has declined (about $10.1M in 2023 to $4.9M in 2024), profitability is materially negative (TTM net loss about $14.6M; 2024 net loss about $53.0M), and cash burn is heavy with persistently negative operating and free cash flow (TTM OCF about -$51.1M; TTM FCF about -$51.2M). The balance sheet helps (low debt; positive equity around $66.3M TTM), but continued losses and cash outflows create funding/runway risk.
Income Statement
18Very NegativeBalance Sheet
62PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 4.91M | 10.09M | 0 | 0 |
| Gross Profit | 0 | 0 | 4.91M | 10.09M | 0 | 0 |
| EBITDA | -62.54M | -38.85M | -52.68M | -47.37M | -45.69M | -41.88M |
| Net Income | -67.15M | -38.97M | -53.04M | -47.92M | -46.18M | -42.29M |
Balance Sheet | ||||||
| Total Assets | 91.95M | 53.02M | 45.21M | 103.95M | 85.65M | 126.49M |
| Cash, Cash Equivalents and Short-Term Investments | 87.69M | 48.91M | 38.75M | 96.34M | 79.08M | 88.97M |
| Total Debt | 8.32M | 736.00K | 2.77M | 4.61M | 6.32M | 6.53M |
| Total Liabilities | 25.65M | 10.51M | 16.39M | 27.44M | 17.16M | 15.12M |
| Stockholders Equity | 66.30M | 42.52M | 28.82M | 76.51M | 68.49M | 111.37M |
Cash Flow | ||||||
| Free Cash Flow | -51.21M | -33.33M | -55.96M | -33.28M | -41.69M | -35.97M |
| Operating Cash Flow | -51.07M | -33.33M | -55.96M | -33.27M | -41.68M | -35.88M |
| Investing Cash Flow | -145.00K | 0 | 0 | 55.78M | 23.69M | -79.17M |
| Financing Cash Flow | 128.24M | 43.48M | -1.62M | 49.14M | -241.00K | 643.00K |
Spruce Biosciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SPRB, the sentiment is Negative. The current price of 43.31 is below the 20-day moving average (MA) of 44.85, below the 50-day MA of 47.22, and below the 200-day MA of 54.06, indicating a bearish trend. The MACD of -0.31 indicates Negative momentum. The RSI at 45.78 is Neutral, neither overbought nor oversold. The STOCH value of 30.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SPRB.
Spruce Biosciences Risk Analysis
Spruce Biosciences disclosed 74 risk factors in its most recent earnings report. Spruce Biosciences reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksSpruce Biosciences Peers Comparison
Overall Rating
FBIO64Neutral
DTIL54Neutral
SPRB47Neutral
CLNN45Neutral
IMUX40Underperform
IMA39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 64Neutral | $62.70M | 0.65 | 74.69% | ― | 12.34% | ― | |
| 54Neutral | $211.33M | -6.15 | -58.09% | ― | 6353.01% | 84.80% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $124.47M | -1.24 | -118.22% | ― | -100.00% | 58.95% | |
| 45Neutral | $56.45M | -1.63 | 175.40% | ― | 11.21% | 30.44% | |
| 40Underperform | $102.61M | -1.68 | -136.26% | ― | ― | 48.29% | |
| 39Underperform | $43.22M | -1.11 | -32.90% | ― | ― | 61.67% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SPRB | Spruce Biosciences, Inc. | 43.31 | -65.53 | -60.21% | |
| IMUX | Immunic, Inc. | 7.52 | 0.22 | 3.01% | |
| FBIO | Fortress Biotech Inc | 1.88 | -0.73 | -27.97% | |
| CLNN | Clene Inc | 3.92 | -4.69 | -54.47% | |
| DTIL | Precision Biosciences | 7.57 | 2.43 | 47.18% | |
| IMA | Imagenebio, Inc. | 3.47 | -4.23 | -54.94% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026
